ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.
Melanoma and other Skin Tumours
Latest ESMO videos
Featured medwireNews
Stage III High-Risk Melanoma Benefits With Dabrafenib–Trametinib, Pembrolizumab
Continuous BRAF–MEK inhibition Best For BRAF-Mutated Melanoma
Immune-Related Adverse Event Risks Differ By ICI Regimen in Advanced Melanoma
COMBI-AD Biomarker Analysis May Help Guide Stage III Melanoma Care
Cemiplimab Active, Well Tolerated For Locally Advanced Cutaneous SCC
E-Learning
ESMO V-Learning: BRAF Mutations Across Cancers
ESMO E-Learning: New Treatments in Melanoma
ESMO V-Learning: Inhibition of MEK to Treat Cancer, focussing on Melanoma
Factsheets on Biomarkers
PD-L1 in Cancer: ESMO Biomarker Factsheet
NRAS in Melanoma: ESMO Biomarker Factsheet
BRAF in Melanoma: ESMO Biomarker Factsheet
Meeting resources
Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
Presenter: Gil Awada
Session: Poster Display & Cocktail
Resources:
Abstract
Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
Current Standards of Care and Practice Changing Studies in Early Melanoma
Presenter: C. Robert, FR
Session: Session 5 Development in Systemic Therapies
Resources:
Case Presentation: Early Melanoma
Presenter: Q. Mbalo, ZA
Session: Session 5 Development in Systemic Therapies
Resources:
Current Standards of Care and Practice Changing Studies in Advanced Melanoma
Presenter: C. Robert, FR
Session: Session 5 Development in Systemic Therapies
Resources: